Celesio sells its subsidiary and mail-order pharmacy DocMorris N.V., Heerlen, as well as the DocMorris trademark to the Swiss pharmaceutical distributor Zur Rose AG. The purchase price amounts to 25 million euro; this entails additional impairment losses amounting to approximately 30 million euro. These will already be considered in the interim report as of 30 September 2012. Celesio confirms its expectations for the 2012 fiscal year and assumes that adjusted EBITDA for 2012 will at least match the 2011 level with a minimum of 550 million euro. The sale of DocMorris is part of Celesio’s strategy to expand the collaboration with local pharmacies through innovative services. By doing so, Celesio aims to strengthen pharmacies in their increasing role in providing effective and efficient healthcare.